With effective treatment currently limited to smoking cessation, REDUCE-IT aimed to evaluate the effects of icosapent ethyl on cardiovascular risk in patients with a history of smoking. In this touchCARDIO interview, we speak with Dr Michael Miller (Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA) to discuss the post hoc analysis of REDUCE-IT and its implications for icosapent ethyl treatment for patients.Â
The abstract entitled ‘Icosapent Ethyl diminishes CVD risk in smokers: REDUCE-IT smoking’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
Questions:
- What was the rationale for the post-hoc analysis of the REDUCE-IT data by smoking status? (0:31)
- What were the findings of this analysis? (1:20)
- On the basis of these findings, what are your recommendations for icosapent ethyl treatment in smokers? (3:09)
Disclosures: Michael Miller is a consultant for Amarin.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Cardiovascular Risk here
Additional Resources: Miller M, Bhatt DL, Steg PG, et al. Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking. Eur Heart J Cardiovasc Pharmacother. 2022;pvac045. doi: 10.1093/ehjcvp/pvac045
